Literature DB >> 1657858

Mechanisms by which endothelin 1 induces pulmonary vasoconstriction in the rabbit.

J Mann1, I S Farrukh, J R Michael.   

Abstract

To investigate the mechanisms by which endothelin 1 (ET-1) causes pulmonary vasoconstriction, we studied the effect of synthetic ET-1 on pulmonary vascular tone in the buffer-perfused isolated rabbit lung. In nanomolar concentrations (1.2-8 nM), ET-1 causes a dose-dependent increase in pulmonary arterial pressure that persists for greater than or equal to 1 h (increase in pressure 19 +/- 2 mmHg with ET-1 vs. 2 +/- 1 with vehicle, P less than 0.0001). Reduction of calcium availability with verapamil, cadmium, or a calcium-free buffer significantly blunts the increase in pressure caused by ET-1. Pretreatment with a calcium-free buffer plus the chelator ethylene glycol-bis(beta-aminoethyl ether)-N,N,N', N'-tetraacetic acid (EGTA) completely eliminates the vasoconstriction. Three different inhibitors of protein kinase C, phloretin, staurosporine, and dihydrosphingosine, significantly diminish the response to ET-1. Indomethacin and a thromboxane synthase inhibitor partially decrease the response to the highest concentration of ET-1. Isoproterenol and dibutyryl adenosine 3',5'-cyclic monophosphate (cAMP) are significantly more effective in preventing the vasoconstriction caused by ET-1 than are nitroprusside and guanosine 5'-cyclic monophosphate (cGMP) analogues. ET-1 in doses of 1.2-8 nM is a potent pulmonary vasoconstrictor in the isolated rabbit lung. ET-1 appears to cause pulmonary vasoconstriction by increasing calcium entry and by activating protein kinase C. Vasodilators that increase cAMP are substantially more effective in preventing the increase in pressure than are drugs that increase cGMP.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1657858     DOI: 10.1152/jappl.1991.71.2.410

Source DB:  PubMed          Journal:  J Appl Physiol (1985)        ISSN: 0161-7567


  9 in total

1.  Effect of carbon dioxide on pulmonary vascular tone at various pulmonary arterial pressure levels induced by endothelin-1.

Authors:  I-Chun Chuang; Huei-Ping Dong; Rei-Cheng Yang; Tung-Heng Wang; Jen-Hsiang Tsai; Pei-Hsuan Yang; Ming-Shyan Huang
Journal:  Lung       Date:  2010-03-09       Impact factor: 2.584

Review 2.  The role of dihydrosphingolipids in disease.

Authors:  Ruth R Magaye; Feby Savira; Yue Hua; Darren J Kelly; Christopher Reid; Bernard Flynn; Danny Liew; Bing H Wang
Journal:  Cell Mol Life Sci       Date:  2018-12-06       Impact factor: 9.261

3.  Update on PPHN: mechanisms and treatment.

Authors:  Jayasree Nair; Satyan Lakshminrusimha
Journal:  Semin Perinatol       Date:  2014-03       Impact factor: 3.300

4.  PKCζ-NADPH Oxidase-PKCα Dependent Kv1.5 Phosphorylation by Endothelin-1 Modulates Nav1.5-NCX1-Cav1.2 Axis in Stimulating Ca2+ Level in Caveolae of Pulmonary Artery Smooth Muscle Cells.

Authors:  Jaganmay Sarkar; Tapati Chakraborti; Pijush Kanti Pramanik; Priyanka Ghosh; Amritlal Mandal; Sajal Chakraborti
Journal:  Cell Biochem Biophys       Date:  2020-10-23       Impact factor: 2.194

Review 5.  Pharmacologic strategies in neonatal pulmonary hypertension other than nitric oxide.

Authors:  Satyan Lakshminrusimha; Bobby Mathew; Corinne L Leach
Journal:  Semin Perinatol       Date:  2016-01-14       Impact factor: 3.300

6.  Inhibition of basal and stimulated release of endothelin-1 from guinea pig tracheal epithelial cells in culture by beta 2-adrenoceptor agonists and cyclic AMP enhancers.

Authors:  Quan Yang; Bruno Battistini; Stéphane Pelletier; Pierre Sirois
Journal:  Inflammation       Date:  2007-10       Impact factor: 4.092

7.  Bacillus anthracis edema toxin inhibits hypoxic pulmonary vasoconstriction via edema factor and cAMP-mediated mechanisms in isolated perfused rat lungs.

Authors:  Xizhong Cui; Jeffrey Wang; Yan Li; Zoe G Couse; Thomas F Risoleo; Mahtab Moayeri; Stephen H Leppla; Daniela Malide; Zu-Xi Yu; Peter Q Eichacker
Journal:  Am J Physiol Heart Circ Physiol       Date:  2020-10-16       Impact factor: 4.733

Review 8.  Hypoxic pulmonary vasoconstriction.

Authors:  J T Sylvester; Larissa A Shimoda; Philip I Aaronson; Jeremy P T Ward
Journal:  Physiol Rev       Date:  2012-01       Impact factor: 46.500

Review 9.  Pathophysiology and Management of Persistent Pulmonary Hypertension of the Newborn.

Authors:  Yogen Singh; Satyan Lakshminrusimha
Journal:  Clin Perinatol       Date:  2021-08       Impact factor: 2.642

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.